Leading industry experts from some of the most influential pharmaceutical, biotech companies, and institutions in the world such as Bristol Myers Squibb, Boehringer Ingelheim, and the Huntsman Cancer Institute will provide insight on using high throughput surface plasmon resonance (SPR) technology to explore the full kinetic and epitope diversity of antibody libraries.
The symposia will take place in Cambridge, MA (September 10, 2019), San Diego, CA (September 17, 2019), San Francisco (September 19, 2019) and Munich, Germany (October 8, 2019). Presentations from leading industry experts and Carterra will demonstrate how high throughput SPR using the Carterra LSA™ is facilitating a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline. This essentially combines screening and detailed characterization in the same step to increase efficiency and productivity and to reduce expenditure during drug discovery and development. For detailed schedules and registration information for...
Christopher Silva, Vice President of Marketing at Carterra commented: “Our upcoming symposia series will provide attendees with real-world examples of the LSA applications in drug discovery. Following our recent expansion into Europe with the opening of a new Customer Experience Center in Munich, Carterra customers are excited to spread the word about our revolutionary platform to even more scientists across the US and in Europe.”
Recent updates to the Carterra website highlight the therapeutic areas where high throughput SPR is making a difference from cancer (immuno-oncology) and heart disease to infectious diseases/vaccines, autoimmune diseases, and pain. The impact of the Carterra LSA on different antibody formats including discovery platforms, bispecifics, antibody-drug conjugates (ADCs), and CAR-T therapy is also explained in detail.
Dr Yasmina Abdiche, PhD, Chief Scientific Officer at Carterra elaborated: “The Carterra LSA is a high throughput SPR platform that is disrupting antibody analytics. The LSA can measure the binding kinetics and affinities of hundreds of interactions in parallel and perform comprehensive epitope binning experiments on up to 384 antibodies per chip. With the additional advantages of minimal sample consumption and industry-leading analysis software, the LSA is streamlining the library-to-leads triage by saving time, cost, and resources in discovering clinically-ready molecules for a number of diseases and conditions.”
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
